Breaking Finance News

HC Wainwright announced Summit Therapeutics PLC (ADR) (NASDAQ:SMMT), boosting its stock price target to $26.00 today

Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) had its estimated target price increased to $26 by HC Wainwright in a report issued 9/16/2016. The updated target price indicates a possible upside of 3.73% based on the company’s last closing price.

Previously on 9/14/2016, Zacks Investment Research released a statement about Summit Therapeutics PLC (ADR)(NASDAQ:SMMT) raised the target price from $0.00 to $7.00. At the time, this indicated a possible upside of 0.12%.

Only yesterday Summit Therapeutics PLC (ADR) (NASDAQ:SMMT) traded 12.00% lower at $5.50. The company’s 50-day average is $6.74 and its two hundred day moving average is $7.48. The last stock close is down 26.49% from the 200-day average, compared to the S&P 500 Index which has fallen -0.01% over the same period. Trade volume was was up over the average, with 21,721 shares of SMMT changing hands over the typical 4,155 shares..

Performance Chart:

Summit Therapeutics PLC (ADR) (NASDAQ:SMMT)

Summit Therapeutics PLC (ADR) has a one-year low of $4.26 and a 52 week high of $12.78 and has a total market value of $0.0.

In addition to HC Wainwright reporting it’s price target, a total of 4 equity analysts have reported on Summit Therapeutics PLC (ADR). The 12-month target price is $22.00 with 0 rating the stock a strong buy, 0 rating the stock a buy, 0 analysts rating the stock a hold, 0 rating the stock to underperform, and lastly 0 brokeragesrating the stock as sell.

About Summit Therapeutics PLC (ADR) (NASDAQ:SMMT)

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, and which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *